Chromoblastomycosis is persistent and is still considered a neglected type of mycosis which is of a subcutaneous location and various fungi of the family Herpotrichiellaceae cause it. As research service providers, we seek therapy advancement in the chromoblastomycosis field as well as other infectious diseases and provide integrated services assisting researchers and scientists associated with the respective field.
Overview of Chromoblastomycosis
Chromoblastomycosis is a chronic fungal infection that penetrates the skin and tissues under the skin. It is caused by fungi like Fonsecaea pedrosoi, Cladophialophora carrionii, and Phialophora verrucosa. These fungi belong to the Herpotrichiellaceae family. Chromoblastomycosis is found in the tropics and subtropics in the following proportions; It has an average prevalence of 1:6800 in Madagascar and 196:1 000 in Brazil. It appears in different forms which include nodular, tumoral type, verrucous, plaque, and cicatricial types.
Fig.1 Acquired immune responses and outcome of chromoblastomycosis. (Passero, L. F. D., et al., 2021)
Pathogenesis of Chromoblastomycosis
The cause of chromoblastomycosis is related to the sharp insertion of fungal spores into the skin and chronically granulomatous lesions forming. This chronicity stems from these fungi's capacity to avoid the immune response and produce biofilms, complicating therapeutic. The fungal entity several days post-infection transforms muriform cells surrounded with phagocytic cells. These muriform or sclerotic cells are altered and round in shape with multicellular septation and are pigmented.
Fig.2 A prototype scheme of induction of innate immunity in chromoblastomycosis. (Passero, L. F. D., et al., 2021)
Vaccine and Therapeutic Development for Chromoblastomycosis
| Types |
Names |
Mechanism of Action |
Targets |
Research Phase |
| DNA Vaccine |
DNA-hsp65 vaccine |
Reduction in NO production |
Hsp65 |
Preclinical research |
| Small molecule drug |
Amphotericin B |
Formed channels that cause leakage of fungal cell components and death |
Ergosterol |
Approved |
| Itraconazole |
Inhibit the demethylation of lanosterol and consequently the production of fungal ergosterol |
CYP51A1 |
Approved |
| Acitretin |
Inhibit endothelial growth and angiogenesis |
RARs |
Approved |
| Imiquimod |
Stimulate the immune response |
TLR 7/8 |
Approved |
| Ajoene |
Inhibit the biosynthesis of phosphatidylcholine, a cell membrane component |
/ |
Clinical research |
| Monoclonal antibody |
Mab anti-GlcCer |
Fungistatic and fungicidal activities |
GlcCer |
Preclinical research |
| Purified antibodies anti-Melanin |
Fungicidal activities |
Melanin |
Preclinical research |
| Photodynamic therapy |
Methylene blue-LED |
Product reactive oxygen species and other reactive molecules |
/ |
Clinical research |
Our Services
Using a sophisticated platform built for disease modeling, vaccine, and therapeutics development, our company connects to an array of tools, technologies, and expertise necessary to unravel the pathogenesis, develop therapy modalities, and examine the possibilities of treating diseases such as chromoblastomycosis.
Featured Services for Chromoblastomycosis
Infectious Disease Models
- CD8 KO model of Fonsecaea pedrosoi infection
- IL-10 KO model of Fonsecaea pedrosoi infection
- CD4 KO model of Fonsecaea pedrosoi infection
- Athymic nude mice model of C. carrionii infection
- Others
Why Choose Us
Fighting these complicated infections and understanding them more deeply requires ample resources. We combine state-of-the-art laboratory facilities with unrivaled research services, expert consultation, and resources that help you gain ground-breaking in the drug development field of infectious diseases.
If you wish to understand our service more in detail, please contact us so we may provide information that is more suited to the demands of your specific research.
References
- Passero, Luiz Felipe Domingues et al. "Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis." Journal of immunology research (2021): 9742832.
- Breda, Leandro C D et al. "Immune Sensing and Potential Immunotherapeutic Approaches to Control Chromoblastomycosis." Journal of fungi (Basel, Switzerland) 7.1 (2020): 3.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
